Geron Corp (NASDAQ:GERN)

CAPS Rating: 3 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Recs

0
Player Avatar RAHJAH (< 20) Submitted: 9/1/2012 8:42:17 AM : Outperform Start Price: $1.50 GERN Score: -34.74

Multiple transformative drug candidates in the pipeline. Limited downside, unmatched upside if base technology works.

Featured Broker Partners


Advertisement